DUBLIN — Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced the presentation of 11 scientific abstracts with findings from the latest clinical and health economics research with TERLIVAZ® (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function during the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting, taking place November 10-14, 2023 in Boston, MA.
Included among Mallinckrodt’s breadth of data for adults with HRS with rapid reduction in kidney function are three oral presentations and one Poster of Distinction detailing research of clinical outcomes with TERLIVAZ and real-world health economics outcomes for TERLIVAZ-treated patients with comorbidities.
TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with HRS with rapid reduction in kidney function, an acute and life-threatening condition requiring hospitalization. HRS involving rapid reduction in kidney function is estimated to affect more than 35,000 Americans annually and rates of HRS hospitalizations are increasing
“It is essential to continue research into the relationship between TERLIVAZ treatment and key factors impacting clinical outcomes, such as concomitant treatments, comorbidities, and real-world care environments, to provide further insights into the continued use of TERLIVAZ for patients with this critical condition,” said Khurram Jamil, MD, Vice President, Hepatology, Clinical Development & Critical Care. “We are thrilled to be able to share findings from our 11 scientific presentations at this year’s AASLD Liver Meeting with the medical community – a testament to the breadth and depth of Mallinckrodt’s commitment to expanding our collective knowledge of HRS to help physicians diagnose and treat HRS patients as early and effectively as possible.”
About Hepatorenal Syndrome (HRS)
Hepatorenal syndrome (HRS) involving rapid reduction in kidney function is an acute and life-threatening condition that occurs in people with advanced liver disease. HRS is classified into two distinct types – a rapidly progressive type that leads to acute renal failure where patients are typically hospitalized for their care and a more chronic type that progresses over weeks to months. HRS involving rapid reduction in kidney function is estimated to affect more than 35,000 Americans annually and rates of HRS hospitalizations are increasing. If left untreated, HRS with rapid reduction in kidney function has a median survival time of approximately two weeks and greater than 80 percent mortality within three months.
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
CONTACTS
Media Inquiries
Green Room Communications
954-816-6003
[email protected]
Investor Relations
Daniel J. Speciale
Senior Vice President, Finance and Chief Financial Officer, Specialty Generics
314-654-3638
[email protected]
Derek Belz
Vice President, Investor Relations
314-654-3950
[email protected]